• Daniela Rezende Garcia Junqueira, Thércia Guedes Viana, Eliane R de M Peixoto, Fabiana C R de Barros, CarvalhoMaria das GraçasMd, and Edson Perini.
• Universidade Federal de Minas Gerais, Brazil. danirgj@terra.com.br
• Rev Assoc Med Bras (1992). 2011 May 1; 57 (3): 322326322-6.

ObjectiveTo investigate the biological origin of injectable unfractioned heparin available in Brazilian market by discussing the impact of the profile of commercial products and the changes in heparin monograph on the drug safety.MethodsThe Anvisa data base for the Registered Products of Pharmaceutical Companies and the Dictionary of Pharmaceutical Specialties (DEF 2008/2009) were searched. A survey with industries having an active permission for marketing the drug in Brazil was conducted.ResultsFive companies were granted a permission to market unfractioned heparin in Brazil. Three of them are porcine in origin and two of them are bovine in origin, with only one explicitly showing this information in the package insert. The effectiveness and safety of heparin studied in non-Brazilian populations may not represent the Brazilian reality, since most countries no longer produce bovine heparin. The currently marketed heparin has approximately 10% less anticoagulant activity than that previously produced and this change may have clinical implications.ConclusionsEvidence about the lack of dose interchangeability between bovine and porcine heparins and the unique safety profile of these drugs indicates the need to follow the treatment and the patients' response. Events threatening the patient's safety must be reported to the pharmacovigilance system in each particular country.

12 keywords...

hide…